Hinge Health, Inc.

HNGE

NYSE; business equipment; SIC 7374, Services-Computer Processing & Data Preparation; CIK 0001673743

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $744.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Mar 3, 2026 248 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$115.96 2026-11-05; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients and members. We have designed our platform to address a broad spectrum of MSK care-from acute injury, to chronic pain, to post-surgical rehabilitation.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 8.8						
Gross profitability	62.9%	28.7%		8.8	555	2025-12-31
Return on invested capital	not computable	11.4%				
one or more required annual facts are missing						
Accruals ratio	not computable	(7.3%)				

a prior annual assets observation is required						
Gross margin stability, five years	not computable	2.3 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 71.9						
Twelve-month failure probability	not computable	0.05%				
liabilities and a nearby cover-page share count are required at 2026-06-30						
Altman Z double-prime	(7.51)	2.18		79.1	565	2025-12-31
Net debt to EBITDA	not computable	1.08x				
one or more required annual facts are missing						
Interest coverage	not computable	3.77x				
one or more required annual facts are missing						
Current ratio	1.47x	2.01x		64.7	663	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	6.4%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	18.0%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	13.5%				
a prior annual working-capital observation is required						
Asset growth, three years	not computable	5.1%				
four annual observations are required; found 1						
Net share issuance, one year	not computable	0.5%				
two annual share counts are required; found 1						

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	95.4%	(2.0%)	90
Distance from 52-week high	(4.0%)	(37.7%)	91
EBIT to enterprise value	not computable	1.8%	
Free cash flow yield	not computable	3.0%	
Book value to price	not computable	0.30	
Sales to price	not computable	0.33	
Composite equity issuance, five years	not computable	4.2%	
Relative strength against the sector, log excess return	0.40	(0.29)	90

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$286.2M
Operating cash flow, four quarters	$290.8M
Months of runway	not finite
Days since last periodic filing	92 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$170.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$468.2M	2025-12-31	2026-03-03	10-K	26-013808
2	assets	us-gaap:Assets	$744.8M	2025-12-31	2026-03-03	10-K	26-013808
3	net income	us-gaap:NetIncomeLoss	-$528.3M	2025-12-31	2026-03-03	10-K	26-013808
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$171.4M	2025-12-31	2026-03-03	10-K	26-013808
5	current assets	us-gaap:AssetsCurrent	$533.9M	2025-12-31	2026-03-03	10-K	26-013808
6	current liabilities	us-gaap:LiabilitiesCurrent	$362.4M	2025-12-31	2026-03-03	10-K	26-013808
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.1B	2025-12-31	2026-03-03	10-K	26-013808
8	operating income	us-gaap:OperatingIncomeLoss	-$546.4M	2025-12-31	2026-03-03	10-K	26-013808
9	book equity	us-gaap:StockholdersEquity	$178.7M	2025-12-31	2026-03-03	10-K	26-013808
10	liabilities	us-gaap:Liabilities	$366.2M	2025-12-31	2026-03-03	10-K	26-013808
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$587.9M	2025-12-31	2026-03-03	10-K	26-013808
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$708,000	2025-12-31	2026-03-03	10-K	26-013808
13	depreciation amortization	us-gaap:Depreciation	$1.3M	2025-12-31	2026-03-03	10-K	26-013808
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$527.3M	2025-12-31	2026-03-03	10-K	26-013808
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$998,000	2025-12-31	2026-03-03	10-K	26-013808
16	shares outstanding	us-gaap:CommonStockSharesOutstanding	0	2025-12-31	2026-03-03	10-K	26-013808

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.